- Home
- CERO vs ONCO Comparison
CERO vs ONCO Comparison
Compare CERO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- ONCO
- Stock Information
- Founded
- CERO 2017
- ONCO 2018
- Country
- CERO United States
- ONCO United States
- Employees
- CERO N/A
- ONCO N/A
- Industry
- CERO
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- ONCO Health Care
- Exchange
- CERO Nasdaq
- ONCO Nasdaq
- Market Cap
- CERO 8.4M
- ONCO 9.4M
- IPO Year
- CERO N/A
- ONCO 2022
- Fundamental
- Price
- CERO $1.80
- ONCO $0.55
- Analyst Decision
- CERO
- ONCO
- Analyst Count
- CERO 0
- ONCO 0
- Target Price
- CERO N/A
- ONCO N/A
- AVG Volume (30 Days)
- CERO 748.6K
- ONCO 10.0M
- Earning Date
- CERO 02-20-2025
- ONCO 12-10-2024
- Dividend Yield
- CERO N/A
- ONCO N/A
- EPS Growth
- CERO N/A
- ONCO N/A
- EPS
- CERO N/A
- ONCO N/A
- Revenue
- CERO N/A
- ONCO $1,870,605.00
- Revenue This Year
- CERO N/A
- ONCO N/A
- Revenue Next Year
- CERO N/A
- ONCO N/A
- P/E Ratio
- CERO N/A
- ONCO N/A
- Revenue Growth
- CERO N/A
- ONCO N/A
- 52 Week Low
- CERO $1.70
- ONCO $0.32
- 52 Week High
- CERO $1,238.00
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- CERO 32.71
- ONCO 44.00
- Support Level
- CERO $1.77
- ONCO $0.58
- Resistance Level
- CERO $2.22
- ONCO $0.70
- Average True Range (ATR)
- CERO 0.34
- ONCO 0.10
- MACD
- CERO 0.27
- ONCO 0.01
- Stochastic Oscillator
- CERO 6.76
- ONCO 17.33
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.